C4X Discovery Appoints CEO

C4X Discovery (C4XD), a leader in rational drug discovery and design has announced Piers Morgan as Chief Executive Officer with immediate effect. Also appointed to the company’s Board of Directors, Mr Morgan succeeds Dr Sam Williams, who returns to his previous role as a Non-Executive Director of the Company.

Formerly CFO of uniQure, a world leader in gene therapy, Piers also served as CFO on the Boards of Phytopharm and BioAlliance Pharma. Before starting his biotech career at Arrow Therapeutics, Piers spent 10 years in corporate finance with Ernst & Young Lead Advisory and Close Brothers. A qualified Chartered Accountant, he also has a degree in Law and Management Studies from Cambridge University. He is Non-Executive Chairman of Trino Therapeutics Ltd, a Dublin-based immunomodulatory company.

Dr Clive Dix, Chairman of C4XD said “We welcome Piers as CEO. Piers brings considerable experience to C4XD and his expertise will be invaluable as the Company enters this important next phase of its development. The Board’s thanks are also due to Sam Williams for his significant contribution to the company’s recent development and we look forward to Sam’s continued involvement as a Non-Executive Director".

“I am delighted to be joining C4XD at an exciting stage in its development. The Company’s technology is now beginning to generate exciting new data, both in collaborations with pharma and on in-house projects. I believe that increasing acceptance will generate huge benefits in the field of small molecule drug development, enabling the discovery of superior drug candidates much more quickly and efficiently. I look forward to leading C4XD as it continues to build on its innovative technology,” added Mr Morgan.